Wang RF, Wang HY. “Immune targets and neoantigens for cancer immunotherapy and precision medicine.” Cell Res. 2017;27(1):11–37. https://doi.org/10.1038/cr.2016.155.
Tao JH, Cheng M, Tang JP, Liu Q, Pan F, Li XP. “Foxp3, regulatory T cell, and autoimmune diseases.” Inflammation. 2017;40(1):328–39. https://doi.org/10.1007/s10753-016-0470-8.
Callahan MK, Wolchok JD. “At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.” J Leukoc Biol. 2013;94(1):41–53. https://doi.org/10.1189/jlb.1212631.
Calpe S, et al. “The SLAM and SAP gene families control innate and adaptive immune responses.” Adv Immunol. 2008;97:177–250. https://doi.org/10.1016/S0065-2776(08)00004-7.
E. Hajaj et al., “SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint,” eLife, vol. 9, Mar. 2020, https://doi.org/10.7554/eLife.52539
Chambers CA, Kuhns MS, Egen JG, Allison JP. “CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.” Annu Re Immu. 2001;19(1):565–94. https://doi.org/10.1146/annurev.immunol.19.1.565.
Camacho LH. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med. May 2015;4(5):661–72. https://doi.org/10.1002/cam4.371.
Kwok G, Yau TCC, Chiu JW, Tse E, Kwong YL. Pembrolizumab Keytruda Human Vaccines and Immunotherapeutics.Taylor and Francis Inc 2016;12(11):2777–89. https://doi.org/10.1080/21645515.2016.1199310
Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA. PD-L1 inhibitors in the pipeline: promise and progress. OncoImmunology. 2018;7(1):1–11. https://doi.org/10.1080/2162402X.2017.1365209.
J. Radocha, N. W. C. J. van de Donk, and K. Weisel, “Monoclonal antibodies and antibody drug conjugates in multiple myeloma,” Cancers, vol. 13, no. 7. MDPI AG, 2021. https://doi.org/10.3390/cancers13071571.
R. Dada, “Program death inhibitors in classical Hodgkin’s lymphoma: a comprehensive review,” Annals of Hematology, vol. 97, no. 4. Springer Verlag, pp. 555–561, 2018. https://doi.org/10.1007/s00277-017-3226-0.
Willemze R, et al. “WHO-EORTC classification for cutaneous lymphomas.” Blood. 2005;105(10):3768–85. https://doi.org/10.1182/blood-2004-09-3502.
Samimi S, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. Dec. 2010;146(12):1382–8. https://doi.org/10.1001/archdermatol.2010.200.
Çetinözman F, Jansen PM, Vermeer MH, Willemze R. Differential expression of Programmed Death-1 (PD-1) in Sézary syndrome and mycosis fungoides. Arch Dermatol. Dec. 2012;148(12):1379–85. https://doi.org/10.1001/archdermatol.2012.2089.
Saulite I, et al. Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. Oncoimuunology. Mar. 2020;9(1):1738797. https://doi.org/10.1080/2162402X.2020.1738797.
Kantekure K, et al. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am J Dermatopathol. Feb. 2012;34(1):126–8. https://doi.org/10.1097/DAD.0b013e31821c35cb.
Wong HK, et al. Increased expression of CTLA-4 in malignant T cells from patients with mycosis fungoides - cutaneous T-cell lymphoma. J Investig Dermatol. Jan. 2006;126(1):212–9. https://doi.org/10.1038/sj.jid.5700029.
D. M. Weiner, J. S. Durgin, M. Wysocka, and A. H. Rook, “The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: current and future approaches,” Journal of the American Academy of Dermatology, vol. 84, no. 3. Mosby Inc., pp. 597–604, 01, 2021. https://doi.org/10.1016/j.jaad.2020.12.026
Serrels A, et al. Nuclear FAK controls chemokine transcription, tregs, and evasion of anti-tumor immunity. Cell. Sep. 2015;163(1):160–73. https://doi.org/10.1016/j.cell.2015.09.001.
L. Agresta, K. H. N. Hoebe, and E. M. Janssen, “The emerging role of CD244 signaling in immune cells of the tumor microenvironment,” Frontiers in Immunology, vol. 9, no. NOV. Frontiers Media S.A., Nov. 28, 2018. https://doi.org/10.3389/fimmu.2018.02809.
G. Pawelec, “Is there a positive side to T cell exhaustion?,” Frontiers in Immunology, vol. 10, no. JAN. Frontiers Media S.A., p. 111, Jan. 29, 2019. https://doi.org/10.3389/fimmu.2019.00111.
Janiga J, Kentley J, Nabhan C, Abdulla F. “Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.” Leukemia and Lymphoma. 2018;59(3):562–77. https://doi.org/10.1080/10428194.2017.1347650.
Oka T, et al. Serum soluble CD48 levels as a prognostic marker in mycosis fungoides and Sézary syndrome. J Invest Dermatol. Oct 2018;138(10):2286–8. https://doi.org/10.1016/j.jid.2018.03.1519.
Hansen ER, et al. Leukemic T cells from patients with cutaneous T-cell lymphoma demonstrate enhanced activation through CDw60, CD2, and CD28 relative to activation through the T-cell antigen receptor complex. J Investig Dermatol. 1993;100(5):667–73. https://doi.org/10.1111/1523-1747.ep12472333.
Mazzeo E, et al. “The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: principles and indications.” Reports of Practical Oncology and Radiotherapy. 2014;19(2):77–91.
Khodadoust MS, et al. “Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study.” JCO. 2019;38(1):20–8. https://doi.org/10.1200/JCO.19.01056.
Lesokhin AM, et al. “Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study.” J Clin Oncology. 2016;34(23):2698–704. https://doi.org/10.1200/JCO.2015.65.9789.